Efficacy of glutamine-supplemented parenteral nutrition on short-term survival following allo-SCT: A randomized study

Bone Marrow Transplantation

Volumn 41, Issue 12, 2008, Pages 1021-1027

  da Gama Torres, H O ^a   Vilela, E G ^a   da Cunha, A S ^a   Goulart, E M A ^a   Souza, M H C ^a   Aguirre, A C C ^a   Azevedo, W M ^a   Lodi, F M ^a   Silva, A A ^a   Bittencourt, H N S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLGLUTAMINE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GLUTAMINE; METHOTREXATE; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG SUBSTITUTION; FEMALE; GENDER; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOMODULATION; INCIDENCE; INFECTION; INTESTINE MUCOSA PERMEABILITY; LENGTH OF STAY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; SURVIVAL TIME;

ADULT; DIETARY SUPPLEMENTS; FEMALE; GLUTAMINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 47849117191     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.27     Document Type: Article

References (56)

1. Blijlevens NMA. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol 2005; 17: 605-611.
2. Johanson JE, Ekman T. Gastrointestinal toxicity related to bone marrow transplantation: Disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 1997; 19: 921-925.
3. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host-disease: Pathophysiology, clinical manifestations and management. Cancer 2004; 101: 1936-1946.
4. Cheney CL, Abson KG, Aker SN, Lenssen P, Cunningham BA, Buergel NS et al. Body composition changes in marrow transplant recipients receiving total parenteral nutrition. Cancer 1987; 59: 1515-1519.
5. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr 1985; 9: 139-143.
6. Smedmyr B, Wibell L, Simonsson B, Oberg G. Impaired glucose tolerance after autologous bone marrow transplantation. Bone Marrow Transplant 1990; 6: 89-92.
7. Oudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel HJI, Zandstra DF. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med 2001; 27: 84-90.
8. Griffiths RD, Jones C, Palmer TEA. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 1997; 13: 295-302.
9. Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P et al. Parenteral L-alanyl glutamine improves 6-month outcome in critically ill patients. Crit Care Med 2002; 30: 2032-2037.
10. Boelens PG, Nijveldt RJ, Houdijk APJ, Meijer S, van Leeuwen PAM. Glutamine alimentation in catabolic state. J Nutr 2001; 131: 2569S-2577S.
11. Andrew FJ, Griffiths RD. Glutamine: Essential for immune nutrition in the critically ill. Br J Nutr 2002; 87: S3-S8.
12. Déchelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coëffier M, Hecketsweiler B et al. L-alanyl-glutamine dipeptide -supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind multicenter study. Crit Care Med 2006; 34: 598-604.
13. Labow BI, Souba WW. Glutamine. World J Surg 2000; 24: 1503-1513.
14. Kudsk KA. Effect of route and type of nutrition on intestine-derived inflammatory responses. Am J Surg 2003; 185: 16-21.
15. Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R et al Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. Ann Intern Med 1992; 116: 821-828.
16. Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized double blind study). JPEN J Parenter Enteral Nutr. 1993; 17: 407-413.
17. Zaanen HCT, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994; 74: 2879-2884.
18. Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: A randomized, double-blind study. JPEN J Parenter Enteral Nutr. 1999; 23: 117-122.
19. Pytlík R, Benes P, Patorková M, Chocenská E, Gregora E, Procházka B et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: A randomized, double blind, placebo controlled study. Bone Marrow Transplant 2002; 30: 953-961.
20. Blijlevens NMA, Donelly JP, Naber AHJ, Schattenberg AVMB, de Pauw, BE. A randomized, double-blind, placeblo controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer, 2005; 13: 790-796.
21. Muscaritoli M, Grieco G, Capria S, Iori AP, Fanelli FP. Nutrional and metabolic support in patients undergoing bone marrow transplantation. Am J Clin Nutr 2002; 75: 183-190.
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow transplant 1995; 15: 826-828.
23. Vilela EG, Ferrari MLA, Torres HOG, Martins FP, Goulart EM, Lima AS et al. Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease. Dig Dis Sci 2007; 52: 1304-1309.
24. Baker KS, Loberiza Jr FR, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005; 23: 7032-7042.
25. Bittencourt H, Rocha V, Chevret S, Socié G, Espérou H, Devergie A et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-2733.
26. Murray SM, Pindoria S. Nutrition support for bone marrow transplant patients (Cochrane Review). In: The Cochrane Library, Issue 4, Update Software: Oxford, 2007.
27. Brown SA, Goringe A, Fegan C, Davies SV, Giddings J, Whittaker JA. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 281-284.
28. Blijlevens NMA, van't Land B, Donelly JP, M'Rabet L, de Pauw BE. Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 2004; 12: 227-233.
29. Blijlevcns NMA, Donelly JP, M'Rabet L, de Pauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 2005; 35: 707-711.
30. Buchman AL. Glutamine: Commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001; 74: 25-32.
31. Alpers DH. Glutamine: Do the data support the cause for glutamine supplementation in humans? Gastroenterology 2006; 130: S106-S116.
32. Sundstrom GM, Wahlin A, Nordin-Anderson I, Suhr OB. Intestinal permeability in patients with acute myeloid leukemia. Eur J Haematol 1998; 61: 250-254.
33. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation in gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385-396.
34. De-Souza Daurea A, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine. Crit Care Med 2005; 33: 1125-1135.
35. Peeters M, Hiele M, Ghoos Y, Huysmans V, Geboes K, Vantrappen G et al Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: Need for standardsation. Gut 1994; 35: 1404-1408.
36. Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram SG, Murphy B, Jenkins AP et al. Geography of intestinal permeability and absorption. Gut 1999; 44: 483-489.
37. Wilmore DW, Shabert JK. Role of glutamine in immunologic responses. Nutrition 1998; 14: 618-626.
38. Crawford J, Cohen HJ. The essential role of glutamine in lymphocyte differentiation in vitro. J Cell Physiol 1985; 124: 275-282.
39. Juretic A, Spagnoli GC, Horig H, Babst R, von Bremen K, Harder F et al. Glutamine requirements in the generation of lymphokine-activated killer cells. Clin Nutr 1994; 13: 42-49.
40. Spittler A, Winkler S, Gotzinger P, Oehler R, Willheim M, Tempfer C et al. Influence of glutamine on the phenotype and function of human monocytes. Blood 1995; 86: 1564-1569.
41. Parry-Billings M, Evans J, Calder PC, Newsholme EA. Does glutamine contribute to immunosuppression after major burns? Lancet 1990; 336: 523-525.
42. Wallace C, Keast D. Glutamine and macrophage function. Metabolism 1992; 41: 1016-1020.
43. Yassad A, Lavoinne A, Bion A, Daveau M, Husson A. Glutamine accelerates IL-6 production by rat peritoneal macrophages in culture. FEBS Lett 1997; 413: 81-84.
44. Murphy C, Newsholme P. Macrophage-mediated lysis of a B-cell line, TNF-a release from BCG-activated murine macrophages and IL-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism. Clin Sci 1999; 96: 89-97.
45. Furukawa S, Saito H, Inoue T, Matsuda T, Fukatsu K, Han I et al. Supplemental glutamine augments phagocytosis and reactive oxygen intermediate production by neutrophils and monocytes from postoperative patients in vitro. Nutrition 2000; 16: 323-329.
46. Pithon-Curi TC, Schumacher RI, Freitas JJ, Lagranha C, Newsholme P, Palanch AC et al. Glutamine delays spontaneous apoptosis in neutrophils. Am J Physiol Cell Physiol 2003; 284: C1355-C1361.
47. Yoo SS, Field CJ, McBurney MI. Glutamine supplementation maintains intramuscular glutamine concentrations and normalizes lymphocyte function in infected early weaned pigs. J Nutr 1997; 127: 2253-2259.
48. O'Riordain MG, Fearon KC, Ross JA, Rogers P, Falconer JS, Bartolo DC et al. Glutamine supplemental parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection. Ann Surg 1994; 220: 212-221.
49. Lin MT, Kung SP, Yeh SL, Lin C, Lin TH, Chen KH et al. The effect of glutamine-supplemented total parenteral nutrition on nitrogen economy depends on severity of diseases in surgical patients. Clin Nutr 2002; 21: 213-218.
50. Ziegler TR, Bye RL, Persinger RL, Young LS, Antin JH, Wilmore DW. Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: A pilot study. Am J Med Sci 1998; 315: 4-10.
51. Kudsk KA, Wu Y, Fukatsu K, Zarzaur BL, Johnson CD, Wang R et al. Glutamine-enriched total parenteral nutrition maintains intestinal interleukin-4 and mucosal immunoglobulin A levels. JPEN Parenter Enteral Nutr. 2000; 24: 270-274.
52. Fukatsu K, Kudsk KA, Zarzaur BL, Wu Y, Hanna MK, DeWitt RC. TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Shock 2001; 15: 318-322.
53. Coeffier M, Miralles-Barrachina O, Le Pessot F, Lalaude O, Daveau M, Lavoinne A et al. Influence of glutamine on cytokine production by human gut in vitro. Cytokine 2001; 13: 148-154.
54. De Beaux AC, O'Riordain MG, Ross JA, Jodozi L, Carter DC, Fearon KC. Glutamine-supplemented total parenteral nutrition reduces blood mononuclear cell interleukin-8 release in severe acute pancreatitis. Nutrition 1998; 14: 261-265.
55. Ockenga J, Borchert K, Rifai K, Manus MP, Bischoff SC. Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis. Clin Nutr 2002; 21: 409-416.
56. Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 656-664.